KAER focuses on high-dose delivery of therapeutic aerosols to respiratory impaired patients in clinical settings including the ICU and NICU. KAER’s patented SUPRAER™ aerosol delivery system generates solid-phase aerosols from solutions and suspensions that may contain large molecules and/or comprise viscous solutions. The dose rates of the active agent can be 25 times that of nebulizers. Particle sizes between 1.4 and 4 µm mass median aerodynamic diameter can be selected. KAER is supported by a $2M SBIR award from NHLBI for delivery of surfactant aerosol therapy for acute respiratory distress (ARDS). KAER’s other NHLBI funded program ($300k) is targeted at providing surfactant aerosol therapy to neonates in respiratory distress (nRDS). The annual sales for nRDS and ARDS in projected at $280M/year and $1B/year, respectively. KAER is seeking partners and capital to bring this lifesaving technology into the clinic for surfactant and other biologics, anti-infectives and suspensions.
Session ID: 551556